IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,859,849 | -36.7% | 408,758 | -2.0% | 0.00% | -50.0% |
Q2 2023 | $2,936,842 | +50.5% | 417,165 | +30.6% | 0.00% | 0.0% |
Q1 2023 | $1,950,984 | -3.9% | 319,310 | +0.5% | 0.00% | 0.0% |
Q4 2022 | $2,029,854 | -55.0% | 317,661 | -32.5% | 0.00% | -50.0% |
Q3 2022 | $4,508,000 | -12.2% | 470,588 | +1.2% | 0.00% | 0.0% |
Q2 2022 | $5,134,000 | -24.6% | 465,084 | +13.7% | 0.00% | -20.0% |
Q1 2022 | $6,808,000 | -12.7% | 408,890 | +0.1% | 0.01% | 0.0% |
Q4 2021 | $7,799,000 | -16.1% | 408,533 | +8.3% | 0.01% | -16.7% |
Q3 2021 | $9,301,000 | -5.2% | 377,154 | +0.0% | 0.01% | -14.3% |
Q2 2021 | $9,812,000 | -16.1% | 377,089 | +2.0% | 0.01% | -22.2% |
Q1 2021 | $11,699,000 | -27.0% | 369,529 | +7.0% | 0.01% | -25.0% |
Q4 2020 | $16,026,000 | +282.2% | 345,388 | +171.1% | 0.01% | +200.0% |
Q3 2020 | $4,193,000 | -3.7% | 127,384 | -19.7% | 0.00% | 0.0% |
Q2 2020 | $4,354,000 | -53.8% | 158,616 | -49.6% | 0.00% | -63.6% |
Q1 2020 | $9,428,000 | +14.3% | 314,956 | +5.7% | 0.01% | +37.5% |
Q4 2019 | $8,250,000 | +133.0% | 298,044 | +53.2% | 0.01% | +100.0% |
Q3 2019 | $3,541,000 | – | 194,544 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |